DIA Biosimilars 2013

Repligen

Repligen, Pfizer form licensing agreement for spinal muscular atrophy program

Friday, January 4, 2013 11:29 AM

Repligen, a life sciences company based in Waltham, Mass., has entered into an exclusive worldwide licensing agreement with global pharmaceutical company Pfizer to advance Repligen's spinal muscular atrophy (SMA) program, originally in-licensed from Families of SMA (FSMA).

More... »

Cenduit: Now with Patient Reminders

Repligen enrolls first patient in phase I trial of Friedreich’s Ataxia

Monday, March 19, 2012 03:20 PM

Waltham, Mass.-based Repligen has enrolled the first patient in a phase I clinical trial of RG2833 in adult patients with Friedreich’s Ataxia (FA)—a debilitating, life-shortening, degenerative neuro-muscular disorder that currently has no treatment.

More... »

CRF Health – eCOA Forum

Repligen acquires Novozymes business for $23 million

Friday, October 28, 2011 02:06 PM

Repligen has acquired the business of Novozymes Biopharma Sweden in a cash $22.7 million and future potential milestone payments of $5.6 million. This acquisition will elevate Repligen to a world-leading supplier of products for manufacturing biologic drugs with the potential to yield sustainable growth and profitability in fiscal year 2013, beginning April 1, 2012. The combined company is expected to generate total revenues of approximately $50 million in fiscal year 2013.

More... »

Repligen reports phase IIb failure

Wednesday, March 9, 2011 10:54 AM

Waltham, Mass.-based Repligen said its phase IIb study of RG2417, an oral formulation of uridine, failed to reflect a statistically significant distance between the bipolar depression drug and a placebo.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2013 CenterWatch.